The current status of adjuvant treatment for high-risk renal cell carcinoma.

about

The current status of adjuvant treatment for high-risk renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q47912370

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@en

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@nl

type

Item

label

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@en

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@nl

prefLabel

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@en

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@nl

P1476

The current status of adjuvant treatment for high-risk renal cell carcinoma.

@en

P2093

Bulent Yalçın

http://www.w3.org/2001/XMLSchema#string

Burak Bilgin

http://www.w3.org/2001/XMLSchema#string

Didem Şener Dede

http://www.w3.org/2001/XMLSchema#string

Mehmet An Şendur

http://www.w3.org/2001/XMLSchema#string

Muhammed Bülent Akıncı

http://www.w3.org/2001/XMLSchema#string

Mutlu Hızal

http://www.w3.org/2001/XMLSchema#string

P2860

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective

Comprehensive molecular characterization of clear cell renal cell carcinoma.

Renal cell carcinoma.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Adjuvant therapy for renal cell carcinoma: past, present, and future

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Survival rates after resection for localized kidney cancer: 1989 to 2004

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

P304

2017-2020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0352

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28984480

http://www.w3.org/2001/XMLSchema#string